Exploding popularity of Ozempic, Wegovy among privately insured patients may worsen disparities A USC study of prescription data shows that people with Medicaid or Medicare Part D may be missing out on powerful new obesity and diabetes drugs
Roncal-Jimenez C et al
(ii) Stratification and Long-term Follow-up of Maternal-Fetal Outcomes: Short-term outcomes (miscarriage, preterm birth, structural malformations, placental complications, fetal growth abnormalities) and mid-to-long-term outcomes (offspring growth trajectories, metabolic phenotypes) must be pre-defined within a standardized follow-up framework to assess potential metabolic programming risks
Users who quit before 16 weeks often miss the inflection point where results become obvious
Nausea, mild stomach discomfort, and reduced appetite are the most common
For women with GDM, screening for persistent diabetes at 612 weeks postpartum and every 13 years thereafter is recommended (62)